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Abstract
 
HIV-specific cytotoxic T lymphocytes (CTL) are important in controlling HIV replication, but
the magnitude of the CTL response does not predict clinical outcome. In four donors with delayed
disease progression we identified V
 
 
 
13.2 T cell receptors (TCRs) with very similar and unusually
long 
 
 
 
-chain complementarity determining region 3 (CDR3) regions in CTL specific for the
immunodominant human histocompatibility leukocyte antigens (HLA)-B8–restricted human
immunodeficiency virus-1 (HIV-1) nef epitope, FLKEKGGL (FL8). CTL expressing V
 
 
 
13.2
TCRs tolerate naturally arising viral variants in the FL8 epitope that escape recognition by other
CTL. In addition, they expand efficiently in vitro and are resistant to apoptosis, in contrast to
FL8–specific CTL using other TCRs. Selection of V
 
 
 
13.2 TCRs by some patients early in the
FL8-specific CTL response may be linked with better clinical outcome.
Key words: HIV • cytotoxic T lymphocytes (CTL) • T cell receptor • 
cross-reactivity • apoptosis
 
Introduction
 
There is considerable diversity in the rate of HIV-1 disease
progression, with some infected people progressing rapidly
to AIDS whereas others remain asymptomatic and maintain
normal CD4
 
 
 
 T cell counts for a decade or more. Several
mechanisms have been linked with delayed HIV-1 disease
progression: some long-term nonprogressors (LTNPs) are
infected with attenuated strains of HIV-1 (1) and others
have genetic polymorphisms in their chemokine receptor
and MHC genes associated with good prognosis (2). How-
ever, in most cases there is no single mechanism that accounts
for delayed disease progression (for review see reference 3).
LTNPs exhibit strong cellular immune responses to the virus,
both CD4
 
 
 
 (4) and CD8
 
 
 
 T cell responses (5, 6), but it has
not proved possible to distinguish LTNPs from progressors
simply by the magnitude of their CTL response (7). Simi-
larly, a comprehensive study of CD8
 
 
 
 T cell responses gen-
erated against all HIV-1 proteins has shown no correlation
between either the magnitude or the breadth of the response
and plasma viral load (8). This is paradoxical when there is
good evidence that CTLs are the major force controlling
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HIV replication from early infection (for review see refer-
ence 9). Qualitative aspects of CTL activity such as their
specificity and ability to respond to naturally occurring
HIV variants, functional aspects such as perforin content,
cytokine and chemokine secretion pattern, and the prolif-
erative ability of individual CTL clones may also play a part
in mediating viral control. Studies of antigen-specific T
cells using peptide–HLA class I tetrameric complexes (“tet-
ramers”) to look at both quantitative and qualitative aspects
of CTL function in samples taken directly ex vivo, have
shown that the majority of HIV-specific CTL secrete anti-
viral cytokines and chemokines (10), but this ability may
decline with disease progression (11). HIV-specific CTL
are in an unusual intermediate state of differentiation, ex-
pressing CD27 but lacking CD28, which distinguishes
them from other virus-specific CD8
 
 
 
 populations studied
to date (12). This differentiation phenotype is linked with
low perforin expression and reduced cytolytic ability (10),
which has led to speculation that functional impairment of
HIV-specific CTL underlies the ultimate failure of the in-
fected person to control viral replication (13). These obser-
vations raise the possibility that qualitative aspects of the
CTL response may play a part in spontaneous control of
HIV replication in some infected people.
A critical component of the virus-specific CD8
 
 
 
 T cell
response is the selection of CTL-bearing TCRs that effi-
ciently recognize the infected target cell. In most indi-
viduals with HLA–A2, infection with influenza A virus
stimulates expansions of T cells expressing TCRs with
remarkably similar sequences (14): the recent crystallization
of one such TCR–HLA–peptide complex has revealed
how the TCR fits over the exposed peptide main chain,
and the complex is stablized by insertion of a conserved Ar-
ginine residue from the 
 
 
 
 chain complementarity deter-
mining region 3 (CDR3) into a notch between the bound
peptide and the 
 
 
 
 helix of HLA–A2 (15). Similarly, most
people with HLA–B8 and EBV infection select a conserved
TCR in the response to the EBNA-3A antigen (16). The
structure of this TCR complexed with HLA–B8 and the
EBV peptide has shown how efficiently the conserved
TCR interacts with its HLA–peptide target, forming a net-
work of interactions between the TCR and both pep-
tide and HLA molecule and engendering conformational
changes in the CDR loops (17). Previous studies of the
TCR repertoire in the HIV-specific CTL response have
shown oligoclonal TCR usage (18) but no common recep-
tors in unrelated individuals (19, 20). Here we describe se-
lection of a distinctive V
 
 
 
13.2 TCR with remarkable 
 
 
 
chain conservation in CTL expansions that recognize an
immunodominant epitope in HIV-1 nef from four HIV-
infected individuals with HLA–B8 and delayed disease pro-
gression. In contrast to the immunodominant TCRs de-
scribed in influenza A and EBV infection, not all donors
with HLA–B8 and HIV-1 infection who make nef-specific
responses select this TCR. The apparent link with delayed
disease progression suggests that this TCR confers particular
advantages to the host. We show that CTL using this TCR
are more likely to proliferate in vitro and resist apoptosis
than CTL specific for the same epitope from the same or
other donors using other TCRs. Common “escape” vari-
ants in this epitope are frequently selected under CTL pres-
sure, often early in infection (21): however V
 
 
 
13.2-bearing
CTL recognize these variants as efficiently as the index se-
quence (in contrast to B8 nef-specific T cells expressing
other TCRs) and escape variants have not been selected in
donors with the V
 
 
 
13.2 TCR. The V
 
 
 
13.2 TCR is shown
to have a moderately high affinity for HLA–B8 complexed
with either the index or most common escape variant se-
quence. Taken together these data suggest that this unique
TCR is expressed on CTL that are particularly well-
equipped to control HIV replication and that this could be
linked with good clinical outcome in individuals that have
generated a response that includes the V
 
 
 
13.2 TCR.
 
Materials and Methods
 
Patient Samples and HLA Typing.
 
Samples were taken from
members of a well-characterized cohort, established in 1995, of
165 long-term HIV-1–infected volunteers attending clinics in
London who had been enrolled into a nested case-control study
of the biological and behavioral correlates of nonprogression in
HIV-1 infection (22). Of the original cohort: 46 subjects were
defined as LTNPs based on a stable CD4
 
 
 
 T cell count 
 
 
 
500
cells/
 
 
 
l at 8 yr of infection and 92 as slow progressors based on a
CD4
 
 
 
 T cell count 
 
 
 
500 cells/
 
 
 
l at 8 yr of infection. The ma-
jority (95%) of patients were white homosexual or bisexual men.
We studied four donors with HLA–B8 who had been shown to
respond to the FL8 epitope in previous studies (7): their clinical
characteristics are shown in Table I. At the time of analysis, do-
nors 065 and 200 met the definition of LTNPs and donors 005
and 046 were slow progressors. In addition, samples were ana-
lyzed from a rapid progressor (defined as progressing to a CD4
 
 
 
T cell count 
 
 
 
200 mm
 
3
 
 in 5 yr or less after seroconversion) from
the London cohort and two further patients attending an HIV
clinic in Oxford, both of whom were hemophiliac men with
CDC stage IV disease. Donors with primary HIV-1 infection
were adult subjects with a symptomatic viral illness after high risk
sexual exposure to HIV who had been referred to the San Diego
AIDS Treatment Center for evaluation. Acute HIV infection was
defined by detectable plasma HIV RNA and nonreactive HIV
antibody test or indeterminate Western blot assay. Upon diagno-
sis of acute HIV-1 infection, the majority of the subjects were
treated with antiretroviral therapy (ART). Human subjects ap-
proval for these studies was given by the following bodies: The
Central Oxford Regional Ethics Committee, the Ethics Review
Committee of King’s College Hospital, and The University of
California, San Diego, Institutional Review Board. PBMCs were
separated from heparinized blood and either used fresh or cryo-
preserved for subsequent studies. Molecular HLA typing was per-
formed using the Amplification Refractory Mutation system with
sequence-specific primers as described previously (23).
 
Synthesis of Peptide–HLA Tetramers.
 
The HLA molecule
heavy chain cDNAs were modified by substitution of the trans-
membrane and cytosolic regions with a sequence encoding the
BirA biotinylation enzyme recognition site, as described previ-
ously (24). These modified HLA heavy chains, and 
 
 
 
2-micro-
globulin, were synthesized in a prokaryotic expression system
(pET; R&D Systems), purified from bacterial inclusion bodies, 
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solubilized in the presence of denaturant (4 M urea), and allowed
to refold with the relevant peptide by dilution. Refolded mono-
meric complexes were purified by FPLC and biotinylated using
BirA (Avidity), and then combined with PE-labeled streptavidin
(Sigma-Aldrich) at a 4:1 molar ratio to form tetrameric HLA–
peptide complexes (“tetramers”). The tetramers used in these stud-
ies were as follows: HLA–A
 
*
 
0201-SLYNTVATL (A2 gag p17),
HLA–A
 
*
 
0201-ILKEPVHGV (A2 pol), B8-FLKEKGGL (B8 nef),
B8-FLKEQGGL (B8nef Q5), and B8-DIYKRWII (B8 gag p24)
complexes, with HLA–A
 
*
 
0201-NLVPMVATV (A2 CMV) as a
control.
 
Antigens and Antibodies.
 
Peptides were synthesized by FMOC
chemistry, and corresponded to previously defined and optimized
CTL epitopes. Anti-CD8 (Peridinin chlorophyll protein) antibod-
ies were purchased from Becton Dickinson. A panel of V
 
 
 
 anti-
bodies was made available as part of the TCR mAB workshop by
Dr. Margaret Callan (Weatherall Institute of Molecular Medi-
cine). The hybridoma for the V
 
 
 
13.2 antibody was a kind gift
from Dr. Philippa Marrack (University of Colorado, Health Sci-
ences Center, Denver, CO).
 
Cell Surface and Intracellular Staining.
 
Cell surface and intracel-
lular stainings were performed on fresh or carefully thawed cryo-
preserved PBMCs. Titrated tetramers (PE conjugated) were
added for 15 min at 37
 
 
 
C, followed by addition of a panel of ti-
trated unconjugated V
 
 
 
 antibodies, after which rabbit anti–
mouse FITC antibodies were added. The cells were then stimu-
lated with antigenic peptides for 1 h at 37
 
 
 
C, then Brefeldin A
was added and the cells were incubated overnight at 37
 
 
 
C. The
next day the lymphocytes were washed in PBS, 0.5 mM EDTA,
1% BSA, fixed, and permeabilized in FACS Permeabilization
buffer (Becton Dickinson). After washing, the cells were incu-
bated with IFN
 
 
 
-APC and CD8-Peridinin chlorophyll protein
antibodies for 15 min at room temperature. Cells were then
washed and stored in Cell Fix buffer (Becton Dickinson) at 4
 
 
 
C
until flow cytometry analysis was performed. Samples were ana-
lyzed on a Becton Dickinson FACSCalibur.
 
Enzyme-linked Immunospot Assays.
 
Synthetic peptides corre-
sponding to previously defined and otpimized CTL epitopes
were used at a concentration of 10 
 
 
 
M in IFN-
 
 
 
 enzyme-linked
immunospot assays to define CD8
 
 
 
 T cell responses directly ex
vivo, as described previously (25). PHA was always included as a
positive control.
 
Apoptosis Assays.
 
We compared the susceptibility of different
T cell PBMC populations to apoptosis in overnight culture us-
ing the Tunel (terminal deoxynucleotidyl transferase–mediated
dUTP nick end labeling) assay that measures late apoptotic cells
with DNA fragmentation (26). In brief, freshly obtained PBMC
were stained with tetramer and CD8 (tri-color) followed by
staining with TUNEL (FITC) according to the manufacturer’s
protocol (Roche).
 
Establishment of Clones.
 
CTL clones were established from
PBMCs by using appropriate antigen-specific tetramers in combi-
nation with MACS anti-PE microbeads (Miltenyi Biotec). In brief,
tetramers were added to 3–5 million PBMCs, then incubated at
37
 
 
 
C for 20 min. The cells were then washed with cold buffer and
resuspended in 40
 
 
 
l of anti-PE beads, mixed well and incubated
for 15 min at 4–8
 
 
 
C. The cells were then washed and resuspended
in 500 
 
 
 
l cold buffer, and magnetic separation was performed ac-
cording to the manufacturer’s protocol (Miltenyi Biotec). Sorted
tetramer-positive cells were counted and CTL cloning was per-
formed by using a standard protocol as described previously (27).
 
CTL Lysis Assays.
 
CTL lysis assays were performed using
standard 
 
51
 
Chromium release assays. In brief, HLA-matched B cell
lines were labeled with 
 
51
 
Chromium for 1 h and then washed three
times: target cells were then divided and pulsed with peptides at
different concentrations. After another hour of incubation at 37
 
 
 
C,
the peptide solution was then washed off and cells were counted
and cocultured with CTL clones at appropriate effector to target
(E/T) ratios in 96-well plates. The plates were incubated at 37
 
 
 
C
for 4 h, supernatants were harvested, and then counted for radioac-
tivity using a Beta-plate counter (WALLAC). Specific lysis was cal-
culated from the formula: % lysis 
 
 
 
 (experimental counts 
 
 
 
 media
control)/(detergent control 
 
 
 
 media control) 
 
  
 
100%.
To study the off-rate of the variant Q5 peptide, the assay was
modified as follows: targets (B cell lines) were pulsed with 10 
 
 
 
M
peptide and then washed twice and incubated for varying time
periods, as shown. The cells were then harvested, labeled with
Chromium, and washed before culturing with CTL clones.
 
T Cell Receptor Sequence Analysis.
 
RNA was extracted using
Tri-Reagent from CTL clones or from FACS-sorted PBMC af-
ter staining with the FL8 tetramer and subjected to an RT-PCR
amplification technique with a switching mechanism at the 5
 
 
 
end of the RNA transcripts (28). This was performed with
C-region 
 
 
 
 primer: TCRAC: GTCCATAGACCTCATGTC-
TAGCACAG and a C-region 
 
 
 
 primer: TCRBC: ATTCACC-
CACCAGCTCAGCTCCACG.
Sequencing was performed with gel-purified PCR products
using the dideoxy chain-termination method on a Megabase
1000 in the Wellcome Trust Centre for Human Genetics and in
the MRC Human Immunology Unit sequencing facility.
 
Confirmation of TCR CDR3 Sequence from Tetramer-sorted
Cells.
 
FL8 tetramer–positive cells from donor 005 were sorted
using anti-PE magnetic beads (Miltenyi Biotec). mRNA from
sorted cells was extracted using a Microfast RNA isolation kit
(Invitrogen) and cDNA was synthesized using a Smart PCR
cDNA synthesis kit (CLONTECH Laboratories, Inc.). PCR was
performed with a V
 
 
 
13.2-specific primer: TGGTGAGGGTA-
CAACTGCC and a 3
 
 
 
 C-region primer C
 
 
 
: AGGCGGCT-
GCTCAGGCAGTATCTGGAGTCA, with optimized cycles.
The PCR products were then purified and put into TOPO TA
cloning vectors (Invitrogen). Plasmid DNAs from 20 colonies
containing inserts of the correct size were then sequenced in the
MRC Human Immunology Unit sequencing facility.
 
TCR Affinity Measurement Using Surface Plasmon Resonance.
 
Residues 1–201 and 1–247 from the 
 
 
 
- and 
 
 
 
-chains, respectively,
were cloned into Pett22b
 
 
 
 (Novagen), where the 
 
 
 
-chain was in
frame with the COOH-terminal vector his
 
6
 
 tag. Residues 
 
 
 
 thre-
onine 159 and 
 
 
 
 threonine 174 were mutated to cysteines and the
protein expressed in recA
 
 
 
 derivative BL21 (BLR) strain 
 
Esche-
richia Coli
 
 (Novagen) as inclusion bodies. Soluble TCR protein
was refolded and purified as described (15) and diluted to 0.106,
0.313, 0.625, 1.25, 2.5, 5, 10, 20, 40, and 80 
 
 
 
M in Hepes-buff-
ered saline (Biacore) and injected at a flow rate of 10 
 
 
 
l/min over
Research Grade CM5 Sensor chip surfaces onto which 
 
 
 
1,000 re-
sponse units of B8-nef or B8nef-Q5 mutant proteins had been im-
mobilized. Both pMHC class I proteins were enzymatically biotin-
ylated on the COOH terminus and size purified on a Superdex
200 before immobilization on streptavidin-coupled flow cells. Si-
multaneous data collection from single TCR injections for both
pMHCs allowed for direct comparison of binding parameters.
 
Results
 
The HLA–B8-restricted Response to HIV-1 nef Is Dominated
by V
 
 
 
13.2 Usage in Some Donors.
 
Samples from mem-
bers of a well-characterized cohort of long-term HIV-1– 
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infected volunteers, who had been enrolled into a nested
case-control study of the biological and behavioral corre-
lates of nonprogression in HIV-1 infection (29) were stud-
ied using HLA–peptide tetramers for immunodominant
HIV-1 CTL epitopes, selected on the basis of their HLA
type and results from enzyme-linked immunospot analysis
of their CD8
 
 
 
 T cell responses to HIV-1 antigens (7; and
unpublished data). Tetramer-staining populations were co-
stained with a panel of TCR V
 
 
 
 antibodies to determine T
cell receptor usage of the dominant responses. In four do-
nors with HLA–B8 (005, 046, 065, and 200) the response
to the FL8 nef epitope (amino acids 90–97, FLKEKGGL)
was dominated by V
 
 
 
13.2 usage (Table I), accounting for
between 51 and 96% of the FL8-specific population. All
four donors have remained healthy in the absence of ART
for between 13 and 17 yr, but donor 046 had recently pro-
gressed to a CD4
 
 
 
 T cell count of below 300 mm
 
3
 
.
Sequence Similarities in the V 13.2 T Cell Receptors Used
by Different Individuals in the B8 nef Response. CTL clones
were generated from all four donors and all but one ex-
pressed TCR V 13.2. V  usage in the non-V 13.2 popu-
lation was generally heterogeneous, but in donor 046 was
dominated by usage of V 6: a single V 6-expressing clone
was generated from this donor. The T cell receptor se-
quences of these clones were determined (Table II) and
clones expressing identical V 13.2 TCRs were found in
samples taken at time-points between 4 and 6 mo apart in
donors 005 and 200. The CDR3 was defined as starting at
position 95 of V  and finishing at the phenylalanine of the
motif FGXG within J , as described previously (30). There
was a surprising degree of homology in both the length and
sequence of the  -chain CDR3 region of CTL clones from
these unrelated donors. A striking feature was the length of
the CDR3 region, which unusually incorporated the entire
J  segment and was either 15 or 16 amino acids in length.
Analysis of the  -chain sequences revealed no similar con-
servation. It proved very difficult to generate clones that
did not use V 13.2, but the single V 6-expressing clone
generated from donor 046 showed a shorter CDR3 loop,
in keeping with the sequences of other TCRs, which have
a median CDR3 length of 9.7 residues (31).
To confirm that clones generated from our donors were
representative of the tetramer-reactive population in periph-
eral blood, FL8 tetramer-staining cells were separated from
donor 005 PBMCs using magnetic beads. mRNA was ex-
tracted from the tetramer-sorted cells and the TCR CDR3
region was sequenced: sequence analysis of 20 of 20 cloned
products showed an identical CDR3 sequence to those ex-
pressed by the CTL clones generated from this donor.
V 13.2 Usage for B8-restricted CTL May Be Selected in Pri-
mary HIV-1 Infection But Is Not Seen in Rapid Progressors.
The B8 nef FL8 response is an immunodominant response
in both acute primary HIV-1 infection (21) and during
chronic infection (7): however, not all donors making this
response selected a V 13.2 TCR with a similarly long
CDR3 region. We examined three donors with advanced
HIV-1 disease progression: one was a rapid progressor from
the King’s College Hospital cohort and two were donors
Table I. Characteristics of Long-Term Surviving Study Patients
Donor
Sample 
date
First 
positive 
HIV test HLA type CD4 count 
Viral load (RNA copies/
ml using  DNA)
Percent of FL8-specific 
cells using V 13.2
cell/mm3
005 7.25.00 1.11.86 A*0201, A*2402,
B*0801, B*5701,
Cw*0602, Cw*0701,
DRB*0701, DRB*1301
728 38,219 51
065 1.10.02 1.01.85 A*0101, A*0201,
B*0801, B*5701,
Cw*0602, Cw*0701,
DRB*08032, DRB*15011
2,782 18,817 93
200 5.13.02 1987 A2, A*2402,
B*0801, B15,
Cw7, Cw12,
DRB*1301, DRB*0301
569 1,980 96
046 6.23.02 4.08.87 A*0101, A*0201,
B*0801, B*5701,
Cw*0602, Cw*0701,
DRB*08032, DRB*15011
236 365,000 56Dong et al. 1551
from the Oxford Clinic who remained asymptomatic but
had progressed to a CD4  T cell count of 200/mm3. All
three donors generated a substantial population of FL8-spe-
cific cells measured using the B8-FL8 tetramer but no
V 13.2  responding cells (Fig. 1). We then examined cells
from patients who had been referred to the San Diego
AIDS Treatment Center and were defined as having pri-
mary HIV-1 infection on the basis of a symptomatic viral
illness after high risk sexual exposure to HIV with detect-
able plasma HIV RNA and nonreactive HIV antibody test
or indeterminate Western blot assay. 5 out of 10 HLA–B8 
donors with primary HIV-1 infection who had FL8 tet-
ramer responses showed a variable degree of V 13.2 usage
(between 6 and 100%). However, when tetramer-staining
cells were sorted and the TCR sequence was determined,
only one donor had selected a V 13.2 TCR with a similar
CDR3 loop sequence to the four long-term survivors. Be-
cause most of these patients were given ART early in the
course of HIV-1 infection it is not possible to correlate
TCR usage with clinical outcome in this cohort: however,
these data suggest that selection of a V 13.2 TCR with a
homologous CDR3 region is an uncommon event.
HLA–B8-restricted CTL That Use V 13.2 Are Resistant to
Apoptosis. There is increased susceptibility of antigen-
specific CD8  T cells to apoptosis in HIV-1 infection
(32). We compared the extent of apoptosis of different T
cell PBMC populations in overnight culture using the
Tunel (terminal deoxynucleotidyl transferase mediated
dUTP nick end labeling) assay that measures late apoptotic
cells with DNA fragmentation (26). In general, HIV-spe-
cific CD8  T cell populations were more vulnerable to
apoptosis than CMV-specific cells, which showed very lit-
tle evidence of cell death in this assay (Fig. 2 a). There was
a marked difference in the degree of apoptosis in FL8-spe-
cific CD8  T cells between cells expressing V 13.2 and
those using other TCRs, with the non-V 13.2 population
showing levels of cell death comparable to other HIV-spe-
cific CTL, although very little apoptosis was detected in
the V 13.2 T cells. Using samples from donor 005, in
whom the B8 nef-specific response contains both V 13.2
positive and negative cells, we found that the non-V 13.2
population (although representing almost 50% of the FL8-
specific response in fresh blood) could no longer be de-
tected when cryopreserved cells from the same time-point
were thawed (Fig. 2 b). Similarly, when PBMCs from
donor 005 were cultured overnight in R/10, only the
V 13.2-expressing population could be detected the fol-
lowing day (unpublished data). This is consistent with the
relative ease of generating V 13.2  FL8-specific CTL
clones whereas we could only generate one clone using a
non-V 13.2 TCR. Tetramer-staining T cell populations
expressing the V 13.2 TCR showed significant up-regu-
lation of the antiapoptotic molecule Bcl-2 (unpublished
data). Taken together these data demonstrate a striking
difference in susceptibility to apoptosis in CD8  T cells
specific for the same epitope but expressing different TCRs,
Table II. Sequence Analysis of the CDR3 Regions of the T Cell Receptor  - and  -Chains of FL8-specific CTL Clones Derived from Four 
HIV-infected Long-Term–surviving Donors
Donor CDR3 J  V  CDR3 J 
005 CAS SYLPGQGDHYSNQPQH J 1.5 V 26.1 CIV RAPGRADMR J 44
"" " " "
"" " " "
065 CAS SFEAGQGFFSNQPQH J 1.5 ND
200 CAS SFEPGQGFYSNQPQH J 1.5 V 23 CAV PSGAGSYQLT J 28
"" " " "
046 CAS SYEPGQVSHYSNQPQH J 1.5 V 2.1 CAV KASGSRLT J 58
046 (V 14) CAS SALASLNEQF J 2.1 V 14.1 CAY RPPGTYKYI J 40
Figure 1. V 13.2 usage in the FL8-specific population predominates in
HIV-infected donors with a good clinical outcome. Samples from donors
with chronic HIV-1 infection who made an HLA–B8-restricted FL8-specific
response were costained with the HLA–B8 FL8 tetramer and the TCR
V 13.2 antibody. The bars show the proportion of CD8  T cells staining
with the B8–FL8 tetramer, divided into V 13.2 positive (shaded bars)
and negative (unshaded) components. Four donors in the first part of the
graph are untreated, asymptomatic long-term survivors, and the three donors
on the left side of the figure are patients with progressive HIV-1 infection
and a CD4  T cell count  200 mm3.Conserved HIV-specific T Cell Receptor 1552
and suggests that V 13.2 usage is a marker for CTL that
resist apoptosis and survive well under in vitro culture
conditions.
V 13.2 Usage Permits Recognition of the Principal Escape
Variant of the B8 nef Epitope. Several variants of the FL8
epitope are commonly found in the Los Alamos HIV se-
quence database with substitutions at the P5 anchor resi-
due, from lysine to glutamine (Q5), threonine (T5), aspar-
agine (N5), and methionine (M5). The Q5 sequence was
reported to be amongst several epitope variants selected
very early in primary HIV-1 infection in a donor initially
infected with wild-type virus who made a dominant FL8
response and resulted in significantly reduced CTL recog-
nition (21). We studied the ability of bulk T cell popula-
tions from donor 005 to recognize the Q5 escape variant.
Freshly isolated V 13.2  cells responded to both index
and Q5 peptides in a FACS-based assay of IFN-  secre-
tion (Fig. 3 a). However, the non-V 13.2 population re-
sponded exclusively to the index epitope. This result was
confirmed using an antibody against V 6, which stains all
the remaining non-V 13.2 B8 nef tetramer–positive cells
in donor 046. Only the non-V 6 population responded to
the Q5 variant, whereas both V 6-positive and -negative
populations secreted IFN-  in response to the index pep-
tide (unpublished data). We generated V 13.2-expressing
CTL clones from all four donors and these were able to re-
spond to variant peptides Q5, T5, N5, and M5: however, a
single CTL clone from donor 046 that did not express the
V 13.2 TCR recognized only the index variant (Fig. 3 b).
Peptide titrations revealed significant differences between
046 clones with and without the V 13.2 TCR in their
ability to recognize the most common Q5 variant (Fig. 3
c). Further studies using three additional non-V 13.2 FL8-
specific CTL clones generated from some of the serocon-
verter donors showed recognition only of the index variant
and not of peptides with substitutions (Q, T, and M) for
lysine at position 5 (unpublished data).
To assess the stability of HLA–B8 in complex with the
index and Q5 variants of the FL8 epitope we pulsed target
cells with peptide, washed off excess peptide, and then as-
sessed how long after pulsing the cells remained targets in
conventional lysis assays. Although the loss of the Q5 vari-
ant from the target cells surface was more rapid than for the
index peptide, the cells nevertheless retained the variant
peptide for at least 4 h. The reduced stability of HLA–B8
with the Q5 variant is probably sufficient for it to escape
recognition by low affinity CTL clones, but not so great as
to prevent recognition by moderate and high affinity T cell
receptors such as the V 13.2 TCR described here.
Taken together, these data show that the V 13.2 TCR
has the ability to recognize the most common database vari-
ants that would otherwise escape the dominant FL8 CTL
response. In the absence of a selective advantage for viral
variants expressing mutations in the P5 position of the FL8
Figure 2. (A) V 13.2 usage by HIV-specific CD8  T
cells is associated with resistance to apoptosis. This fig-
ure shows the extent of Tunel positivity in different
tetramer staining virus-specific populations as an indi-
cator of early apoptosis in freshly isolated PBMC from
donor 0005, which have been cultured overnight at
37 C. (B) In donors with mixed TCR usage for the
FL8-specific response, the non-V 13.2 cells are lost on
freeze–thawing. Two aliquots of PBMC taken at the
same time from donor 005 are stained with the V 13.2
antibody (x axis) and the FL8–HLA–B8 tetramer (y
axis). The left-hand panel shows staining from fresh
cells whereas the right hand panel shows staining from
a sample that had been cryopreserved and then thawed.Dong et al. 1553
epitope, we predicted that there would be limited sequence
variation in this region in viral isolates from donors with the
V 13.2 TCR. In keeping with this hypothesis, sequence
analysis of proviral DNA in all four long-term surviving do-
nors showed only the index sequence at the FL8 epitope.
The V 13.2 TCR Shows Moderately Strong Affinity for
Both the Index and Q5 Variant of the FL8 Epitope. Recent
biochemical and structural data for the immunodominant
V 17 TCR (JM22) responding to an influenza matrix pep-
tide presented by HLA–A2 have shown that this TCR has
an affinity at the higher end of the range exhibited for
TCR binding to peptide–HLA (15, 33). We used surface
plasmon resonance analysis to determine the binding affin-
ity of the V 13.2 TCR for HLA–B8 complexed with both
the index FL8 peptide and the Q5 variant. Analysis of equi-
librium-binding data by direct nonlinear curve fitting of
the 1:1 Langmuir-binding equation and by Scatchard plots
indicated that the KD values for the wild-type and Q5 mu-
tant epitopes were 3.4 and 13.1  M, respectively, at 25 C
(Fig. 4). This demonstrates that the binding affinities of the
V 13.2 TCR for both index and variant peptides are in the
middle of the range of TCR-binding affinities reported for
functional TCR–MHC class I recognition (34). Similar
studies were undertaken using the V 6 TCR generated
from donor 046, which showed a lower affinity for the in-
dex peptide (35  M) and an affinity for HLA–B8 com-
plexed with the Q5 variant peptide likely to be outside the
range for T cell recognition (66  M).
Discussion
We have identified oligoclonal populations of CD8  T
cells responding to an epitope in HIV-1 nef presented by
HLA–B8 that are characterized by expression of a TCR
Figure 3. (A) V 13.2 usage is associated with cross-recognition of FL8
variants at P5 The FACS plot has been gated on FL8-specific CD8  T
cells from two donors (005 [left] and 046 [right]) with mixed populations
of V 13.2 positive and negative FL8-specific cells, and shows intracyto-
plasmic staining for interferon   (x axis) following 6 h of stimulation with
the index FL8 peptide (top panels) and the Q5 variant peptide in relation
to V 13.2 staining (y axis). The figures show the proportion of cells in
each quadrant. (B) CTL clones expressing the V 13.2 TCR show broad
cross-reactivity against FL8 peptide variants. A panel of FL8-specific CTL
clones from long-term surviving donors 005, 046, 065, and 200 are tested
for recognition of HLA–B8 matched 51-chromium labeled target cells
pulsed with either the index FL8 peptide or a panel of three variant peptides with naturally occurring substitutions at position 5 (Q5, T5, and M5) in a 4-h
cytotoxicity assay. Four of the clones express V 13.2 and the fifth (046–3) does not. The clones are used at an effector to target ratio of 3:1 and the target
cells have been pulsed with 0.25  M peptide before use in the assay. (C) Peptide titrations show distinct patterns of recognition by CTL clones according
to TCR usage CTL clones generated from donor 046, using either V 13.2 (square symbols) or a non-V 13.2 TCR (triangles), are tested for recognition
of target cells pulsed with varying concentrations of either the index FL8 peptide or the Q5 variant. (D) Cells pulsed with the variant peptide make less
stable targets for CTL lysis than do cells pulsed with the index peptide. Target cells expressing HLA–B8 were pulsed with either the index or the Q5
variant peptide for 1 h and then residual peptide was thoroughly washed off. The target cells were harvested at intervals as shown, labeled with chro-
mium, and used in conventional CTL assays with an FL8-specific CTL clone.Conserved HIV-specific T Cell Receptor 1554
 -chain consisting of V 13.2 and an unusually long CDR3
region in which the entire J  segment is represented. The
sequence of the hypervariable CDR3 region shows a re-
markable degree of conservation between unrelated do-
nors. HIV-1 FL8-specific populations using this TCR are
prominent in long-term survivors, but not in donors with
progressive HIV-1 disease, which raises the possibility that
these CTL have an enhanced ability to control HIV-1 rep-
lication in vivo. Two features of CTL expressing the
V 13.2 TCR may contribute to better viral control. First,
these T cells show a significant degree of resistance to
apoptosis in vitro, making them more similar to CMV-spe-
cific CD8  T cells than to other HIV-specific CTL popu-
lations that we have studied. If this property is also present
in vivo then these cells may be particularly well equipped
to kill HIV-infected cells without themselves succumbing
to apoptosis (32). Second, cells expressing this TCR are
able to respond equally well to both the index peptide and
to commonly occurring potential escape variants at posi-
tion 5 of the octamer epitope. This flexibility of recogni-
tion may be a function of the long  -chain CDR3 region
and could confer an advantage on the infected host by lim-
iting the advantage of viral mutations in an immunodomi-
nant CTL epitope. This hypothesis is given weight by the
absence of sequence variation in the FL8 epitope despite
persistent and strong FL8 CTL responses in donors who
have been infected with HIV-1 for between 13 and 17 yr.
The capacity of HIV to mutate in order to escape CTL
recognition from the earliest stages of infection has been
well described in both human studies (21, 35) and in the
simian immunodeficiency virus (SIV)–infected macaque
model (36). The ability of emerging viral variants to evade
dominant CTL responses may pose a significant problem
for vaccine strategies (37). Indeed the impact of HLA-asso-
ciated selection pressure on viral evolution has recently
been demonstrated at the population level (38), clearly
demonstrating the potential of CTL selection to shape the
emerging viral quasispecies. The immunodominant CTL
response to the FL8 epitope has been detected shortly after
seroconversion and was associated with the emergence of
viral variants with coding changes in the epitope over the
ensuing 6 mo (21). The majority of epitope variants had
changes at position 5 of the epitope that were poorly rec-
ognized by the patient’s own CTL. The findings of Price
and colleagues suggest that although the FL8 epitope is
highly immunogenic, the effectiveness of the response is
limited by the ability of the virus to generate variants that
escape the host CTL response. Our observation that only 1
out of 10 seroconverters who mounted an FL8 response se-
lected a TCR with a homologous   chain to the V 13.2
TCR seen in the four long-term survivors suggests that
only a minority of donors can mount a CTL response capa-
ble of recognizing FL8 epitope variants.
When epitope variation abrogates binding of the peptide
to the HLA molecule, all T cell populations will be equally
affected, but epitope variants that impact on the interaction
between the TCR and the peptide-HLA complex may be
tolerated by some TCRs and not by others. We have re-
cently shown that CTL specific for an immunodominant
gag epitope restricted by HLA–B57, an HLA molecule
consistently shown to be associated with delayed HIV-1
disease progression, show a significant degree of tolerance
to the common viral variants of this epitope (39), a phe-
nomenon that may contribute to better viral control. The
apparent association between expression of the V 13.2
TCR and delayed disease progression in this study could
indicate that the capacity to generate a B8 nef response that
includes this TCR facilitates viral control. Although P5 of
the FL8 peptide is an anchor residue that mediates binding
to the HLA–B8 molecule rather than being exposed for di-
rect TCR recognition (40), it is likely that the substitution
of lysine for other residues induces a conformational
change at the surface of the peptide–HLA complex that
could affect TCR recognition of the bound peptide. The
structure of HLA–B8 complexed with another HIV-1 pep-
tide, GGKKKYKL from gag p17, showed that substitutions
at the P3 anchor position caused significant structural alter-
ations at the surface of the peptide–HLA complex, whereas
changes at P5 had more modest conformational impact
Figure 4. Surface plasmon resonance studies show that the V 13.2
TCR has a high affinity for both index and Q5 variant peptides. The
binding affinity of the V 13.2 TCR for HLA–B8 complexed with the in-
dex FL8 peptide was determined by surface plasmon resonance at 25 C. Scat-
chard transformation of specific response units and analysis of the slope by
linear regression indicated that the KD value for the wild-type peptide was
5.5  M.Dong et al. 1555
(40). Similarly, crystal structures of HLA B8 complexed to
the index FL8 and Q5 variant peptides (unpublished data)
again show that the peptide anchor side chain (lysine) at P5
points downward and is involved in stabilizing the peptide
in the groove. The exposed peptide backbone conforma-
tion shows no significant differences between the index
FL8 and Q5 variant, but glutamine acts less efficiently as an
anchor residue, leading to increased mobility of the bound
peptide. Our studies to determine the stability of the HLA–
B8 complexed with either index or Q5 peptide by assessing
how long peptide-pulsed cells remain CTL targets confirm
reduced stability of the the complex with the variant pep-
tide, but we propose that cells expressing the variant
epitope could nevertheless be recognized by T cells ex-
pressing a sufficiently high affinity TCR.
The human T cell receptor  -and  -chains are derived
through the selection and rearrangement of a large number
of variable (V), diversity (D), and joining (J) gene segments:
further complexity is conferred by the addition of N region
nucleotide diversity in the junctional region. The hyper-
variable CDR3 region spans this junctional region and in a
number of MHC–TCR crystal structures has been shown
to interact directly with the peptide epitope held in the
cleft of the MHC class I molecule. The length of the
CDR3 region is relatively conserved in the human TCR
repertoire with a mean of 9.7 residues (standard deviation
1.7) for both   and   chains (31), in contrast to the V 13.2
TCR, which has a CDR3 length of 16 amino acids. The
CDR3 region of the  -chain predominantly contacts the
COOH-terminal half of the peptide, so the advantage of
this TCR may be the flexibility of the long CDR3 region,
allowing it to tolerate viral mutations that alter the confor-
mation of the epitope at position 5 of the peptide. The
binding data for this TCR show that it has an affinity for
HLA–B8 complexed with the index peptide in the middle
of the range reported for other TCRs: thus it is not an un-
usually high affinity TCR but has similar properties to oth-
ers studied to date. The affinity of this TCR for B8 and the
Q5 peptide is lower, but still well within the range de-
scribed for other TCRs. In contrast, the single non-V 13.2
TCR that we have been able to generate with specificity
for the FL8 peptide shows a lower affinity for the B8 index
peptide complex (despite the similar peptide titrations in
conventional CTL assays) and an affinity for the mutant
peptide that is almost certainly outside the range for T cell
recognition. These data provide some explanation for the
immunodominance of the V 13.2 TCR and the extent of
cross-reactivity that it exhibits.
Why should expression of this TCR be associated with
an enhanced ability to proliferate and a striking resistance to
apoptosis compared with the majority of HIV-specific T
cell populations? We noted that this functional phenotype
was associated with the up-regulation of the antiapoptotic
molecule Bcl-2. Although detailed crystallographic data of
the HLA–B8 molecule complexed with the V 13.2 TCR
are still awaited, it is plausible that the stability of the
TCR–peptide–HLA complex formed by the V 13.2 TCR
confers certain survival properties on the memory T cell
population as a function of prolonged stimulation, as re-
cently suggested by Gett and colleagues (41) .
The potential repertoire of different    T cells is
thought to be between 1015 and 1020, far exceeding the
1012 lymphocytes in the adult human. Random selection of
a restricted T cell response in unrelated individuals is there-
fore highly unlikely and has not been described previously
in HIV-1 infection. In primary HIV-1 infection, a narrow
oligoclonal CD8  response in acute infection is associated
with more rapid disease progression, thought to be due to
limited ability to respond to viral escape variants (18). Re-
cent studies have highlighted the diversity of T cells that
respond to the same epitope within and between individu-
als: analysis of TCR usage in the HLA–A2-restricted re-
sponse to a dominant epitope in p17 gag suggested that the
repertoire is selected for its ability to respond to emerging
viral variants, with the response to a single epitope in one
donor eliciting 15 distinct clonotypes (20). Other studies
have shown oligoclonal TCR usage in tetramer-staining
HIV-specific populations but no common features of TCR
usage for HLA–A2 and B27-restricted HIV-specific re-
sponses between different individuals (19, 42). In chronic
SIV infection, the immunodominant response to SIV gag
restricted by Mamu-A*01 is oligoclonal with a preference
for V 13 and conserved CDR3 usage (43): however,
TCR usage can vary over time and a single dominant clone
has not been identified (44).
Highly restricted TCR usage has been described in the
human CTL responses to influenza A matrix in individuals
with HLA–A2, which is dominated by V 17 and V 10 us-
age (14), and in EBV infection, in which donors with
HLA–B8 exhibit striking TCR conservation of both   and
  chains in their response to an immunodominant epitope
in EBNA 3A (16). Our findings in HIV-1 infection differ
in several regards. First, selection for the V 13.2 TCR is
confined to the  -chain with no restriction on  -chain us-
age: the advantage of the V 13.2 TCR may lie principally
in its potential to recognize variants in the COOH-terminal
part of the peptide. Second, highly conserved TCR usage is
seen in most indivuals with HLA–A2 and CTL responses to
influenza matrix, or HLA–B8 and CTL responses to EBV
EBNA-3, whereas our studies in primary HIV-1 infection
suggest that only a minority of infected people with a
strong response to the FL8 epitope can select a V 13.2
TCR homologous to the TCRs from the four long-term
survivors. Although the number of patients we have been
able to study is relatively small, given the frequency of
HLA–B8 (which is not enriched in LTNP cohorts), the
four donors we identified with large populations of V 13.2
TCR B8 nef-specific CD8  T cells have all shown signifi-
cantly delayed disease progression, suggesting that the abil-
ity to select this TCR may be linked with enhanced viral
control. Although further studies with larger numbers of
patients are needed to provide support for this hypothesis,
we propose that individuals who are able to mount an
HLA–B8-restricted response that includes the V 13.2
TCR have a greater ability to control viral replication by
limiting the advantage of potential CTL escape variants.Conserved HIV-specific T Cell Receptor 1556
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